Medvi Reviews, Complaints: GLP-1, Semaglutide, Tirzepatide

The GLP-1 telemedicine space has grown exponentially over the past year due to an explosion in providers that are almost all sounding as though they have very similar products and services, although upon deeper inspection of the product offerings that are available, it quickly becomes clear that many of these providers do have distinct differences.

MedVi is another example of a platform where the benefits become apparent when inspecting closer. THeir surface offering is straightforward: cheap compounded GLP-1 options, fast approval process, no contract obligations and 24 hours per day 7 days per week availability to speak with your physician.

However, this is only part of the picture and there are some additional factors that should be understood prior to registering.

What Is MedVi?

MedVi is a telemedicine company that is based in San Diego. They began operations in 2024.

In general, the company allows its users to connect to a network of both physicians and nurses using the Open Loop Health Network and Beluga Health Networks (both of which are licensed as health care provider networks).

The network of providers used by MedVi will make all the decisions regarding what prescriptions a user receives. This is because MedVi technically does not offer healthcare services; instead it provides software and tools that are designed for use in managing patients.

MedVi has also been granted LegitScript certification. As such, they are subject to continuing monitoring, must adhere to transparency requirements, and must be compliant with all relevant Federal and state laws.

MedVi currently offers its services in forty-nine different states, although North Dakota is the only state where MedVi does not operate.

The states of Kansas, Indiana, Mississippi, New Mexico, Oklahoma and West Virginia require that users complete a “live” consultation with a prescriber prior to receiving a prescription from MedVi.

Users who are located in either Alabama or California and who want to obtain a GLP-1 injection cannot receive oral forms of the drug due to specific regulations related to each state.

How MedVi Works

The initial steps for onboarding with MedVi are intended to be fast. The patient will fill out an extensive health questionnaire. It will include their entire health history, present medications, allergies, and the patients weight loss objectives.

After completing the online health questionnaire, the platform will screen for any contraindication. Examples would include a patient’s family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia Syndrome Type II (MENII).

In most states, there will be an asynchronous review by a physician. That simply means that there will be no live video conference and typically approval will occur within 24 to 48 hours.

After being approved, a treatment program that is tailored to the individual needs of the patient will need to be developed. It will contain the type of medication prescribed, how much of it the patient should take daily, and what kind of support they can expect during the first few weeks of treatment.

Once the treatment program has been completed, a prescription for the medication will go to a partnering pharmacy that compounds medicine. After the pharmacy receives the prescription it will compound the medication and ship it. Shipping generally takes approximately 2 to 3 business days from when the order was fulfilled. Patients will have access to tracking information regarding where their shipment is located at least two business days prior to delivery.

Each month, a patient will submit a refill request to continue their subscription. Submitting this form will give the clinical staff a way to periodically communicate with patients about their progress, any possible side effects experienced, and if any changes need to be made in regards to dosing. Every subscription provided to a patient provides unlimited 24/7 communication capabilities with the clinical staff.

GLP-1 Product Offerings

The list of medications offered by MedVi is limited but effective. Semaglutide is available from MedVi in two different formats: weekly injectable vials and daily dissolvable sublingual tablets. Weekly injectable vials for semaglutide have been the standard delivery format for many compounded GLP-1 programs.

Both MedVi injectable and tablet forms of semaglutide follow the same subcutaneous injection method as Ozempic and Wegovy, but they come from a compounding pharmacy instead of a pharmaceutical company.

MedVi has also developed an innovative and beneficial sublingual tablet version of semaglutide, that can be used once each day, which is dissolvable under the patient’s tongue.

This sublingual version of semaglutide is especially helpful for patients who have difficulty using needles, which addresses an obstacle to care that very few competitors address.

Tirzepatide (dual GLP-1/GIP receptor activator) is also available through MedVi for patients seeking this dual mechanism, as well as their preferred route of administration (injectable or tablet), based upon state regulations and the physician’s decision.

Pricing: What it Actually Costs

MedVi’s pricing structure is arguably among the clearest competitive differentiators it has to offer:

The initial month of compounded Semaglutide (semaglutide) injections costs $179. This is essentially a promotional or introductory price for all services including a physician review, a customized treatment plan, a metabolic report, the medication itself, free shipping, and access to unlimited messaging with your provider. After the first month refills cost $299/month.

Compounded semaglutide tablets are priced at $249/month. Refill pricing for tirzepatide will require confirmation from MEDVi’s customer service prior to committing.

All components of the subscription are included in the monthly fee. Thus there are no additional consultation fees, no surprise laboratory charges on most cases for patients, and no shipping fees.

Pharmacy Sourcing: The 503B Advantage

The platform’s primary pharmacy partner is Belmar Pharma Solutions, which operates both 503A patient-specific compounding pharmacies and an FDA-registered 503B outsourcing facility.

Medvi is the first Telemedicine company to mention the 503b designation as part of their process ( others just use 503a). State regulation applies to 503a pharmacies, whereas federal “Current Good Manufacturing Practices” regulate 503b Outsourced Facilities.

As such, 503b outsourced facilities have higher quality control processes for raw materials and finished products, greater consistency in batches, and additional third-party testing on ingredients and finished goods for compliance prior to distribution.

Cold-Chain Shipping

Medication is shipped by MedVi using temperature-controlled containers with cold packs. The independent reviewers’ confirmation that the medications arrive both cold and in an unbroken condition indicates the consistent nature of the time required to complete shipment (i.e. 2 to 3 working days from when fulfillment occurs).

MedVi only ships on Mondays, Tuesdays and Wednesdays, so there’s no weekend exposure to temperatures during transport. Although MedVi does not make any guarantees regarding a specific temperature range that will be maintained throughout the duration of transportation, their 503-B infrastructure (combined with the fact that reviewers have confirmed that MedVi uses cold packs for delivery) is what provides MedVi with above average cold chain practices within the compounding GLP-1 category as a whole.

Titration: Provider-Directed, Not Billing-Driven

MEDVi’s titration process is truly patient-centric. Through their 24/7 messaging system, patients are able to continuously communicate about side effect issues, tolerance and dosing issues as they develop. This eliminates the need to wait until the next scheduled visit (which may be every 90 days).

In addition, the monthly prescription refill form provides an additional structured clinical interaction for providers to review the effectiveness of treatment from the standpoint of actual patient improvement and determine if a dose adjustment is needed.

Further, unlike many competing products in the tiered pricing format, MEDVi does not increase pricing for compounded Semaglutide injections as the dose increases. This means that patient who has found the optimal effective dose will not experience increased financial pressures to move to a higher dose.

The Off-Ramp: What Happens When Someone Reaches Their Goal

MedVi doesn’t formally document a tapering protocol or provide a lower-cost, “maintenance-only” membership option for those who have reached their desired weight.

Their month-by-month subscription model provides an open-ended opportunity for patients who want to terminate their subscription at any point in time with no penalty associated with terminating a subscription (which allows for true termination of service).

Although MedVi has the clinical mechanisms that are available to support a tapering discussion with a patient, such as via the patient initiated 24/7 messaging system and the monthly refill review process, they are not systematically activated.

Non-Responder Protocol: The 15% Problem

Approximately 15% of semaglutide users (11% of men to 19% of women, to be more specific) have been defined as clinical “non-responders” and those numbers were supported by the most recent data. MEDVi answers this question from a position in the provider relationship with an option for Tirzepatide.

The patient has the ability to bring up at the monthly refill review or via messaging at any point they feel they are not losing enough weight and/or do not see the results they expected while taking Semaglutide. They will be able to access the Tirzepatide path through the same platform.

Prior Authorization

MEDVi operates as a cash-pay only platform. Insurance is not accepted for GLP-1 prescriptions.

There is also no prior authorization process and no insurance navigation team. HSA and FSA payments, however, are eligible.

What Real Patients Are Saying

Based on over 12,000 reviews, MedVi currently has a rating of 4.4 / 5. Positive comments repeatedly mention the speed of the approval process and the fact that results were shown on the website in the first couple of weeks after the injections were given, in addition to MEDVi’s caring and communicative customer service via their messaging system and clearly defined pricing.

Negative comments seem to be centered upon two issues. The first issue is billing cycles. Unlike many other companies, MEDVi bills for its services based on the time elapsed since the date of sign-up with the company (not on the date of the first injection). This can lead to delays in billing if an individual experiences any type of delay in receiving their injections.

The second issue is when a primary care physician has indicated some level of medical necessity prior to allowing an individual to receive injections. In these situations, patients have reported experiencing difficulty navigating through the process while being charged by MedVi.

Who MedVi Makes Sense For

MedVi is ideal for the self-directed patient, who has already determined they would like a GLP-1 compound product.

While there are certainly some gaps present within this system (e.g., no formally established non-responder protocol, no previously published tapering pathway, etc.) the patient will need to take on the responsibility of seeking out information to ensure their needs are met.

Citations

• Aleksic, A. (2025, November 15). 503A vs. 503B Compounding & FDA Regulations Guide — Restore Health Consulting. Restore Health Consulting. https://www.restorehealthconsulting.com/news/503a-vs-503b-compounding-amp-fda-regulations-guide 
• Belmar Pharma Solutions. (2026, April 6). National Compounding Pharmacy | Belmar Pharma Solutions. https://www.belmarpharmasolutions.com/ 
• Fahad, H. (2026c, February 2). MEDVI GLP-1 Clinic review: A flat rate with options – Vaccine alliance. Vaccine Alliance. https://www.vaccinealliance.org/reviews/medvi-glp-1-clinic-review/ 
• (2025, October 16). Compliance Certification: your safety assurance | LegitScript. https://www.legitscript.com/certification/ 
• MEDVI – Personalized Telehealth care. (n.d.). https://home.medvi.org/
• MEDVI GLP-1 Reviews 2026: Compounded semaglutide and tirzepatide safety, Pricing, and the oral tablet absorption question. (2026, April 4). https://utcardiothoracicsurgery.com/medvi-and-the-compounded-glp-1-market-in-2026/
• Mayer, B. A. (2024c, April 20). 5 Reasons Why GLP-1 Drugs like Ozempic and Wegovy May Not Help You Lose Weight. Healthline. https://www.healthline.com/health-news/ozempic-glp-1-drugs-may-not-work
• Predin, J. M. (2026b, April 3). How Medvi found success with just $20,000 and AI. Forbes. https://www.forbes.com/sites/josipamajic/2026/04/02/ai-and-20000-helped-one-man-build-a-18-billion-telehealth-startup/
• (2026i, April 12). MEDVI Reviews. https://www.trustpilot.com/review/medvi.org